Education
About Us
Working with TipRanks
Follow Us
Adaptimmune Therapeutics Plc. (DE:473A)
:473A
RESEARCH TOOLSreports
Earnings Data
Report Date
Aug 06, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.05Last Year’s EPS
0.04Same Quarter Last Year
Moderate Buy
Based on 7 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 13, 2025
|% Change Since: -1.79%
|Next Earnings Date:Aug 06, 2025
Earnings Call Sentiment|Positive
The earnings call reflected strong operational achievements with the successful launch of TECELRA, impressive manufacturing metrics, and expansion of treatment centers. However, ongoing financial concerns about cash runway tempered the positive aspects.Company Guidance
During Adaptimmune's first quarter 2025 business update call, CEO Adrian Rawcliffe provided guidance for TECELRA sales, projecting full-year revenue between $35 million and $45 million. This projection is supported by the 21 patients apheresed so far in 2025, including 13 in Q1 and 8 early in Q2. With 28 authorized treatment centers currently operating and plans to reach 30 by year-end, the company has invoiced for 14 TECELRA treatments, 6 in Q1 contributing to $4 million in net sales, and 8 more invoiced in early Q2. Notably, Adaptimmune achieved a 100% manufacturing success rate with an average turnaround time of 27 days, surpassing their 30-day target. The company anticipates peak sales of $400 million from its TECELRA and lete-cel sarcoma franchise, with lete-cel expected to launch in 2026, targeting broader patient populations without the need for antigen testing in myxoid liposarcoma cases.Successful TECELRA Launch and Revenue Guidance
Adaptimmune launched TECELRA and provided full-year 2025 revenue guidance of $35 million to $45 million, with 21 patients apheresed so far in 2025 and 14 treatments invoiced, generating $4 million in Q1 net sales.
Efficient Manufacturing Operations
Achieved 100% manufacturing success rate from the U.S. TECELRA manufacturing center, with no capacity issues and an average turnaround time from apheresis to lot release of 27 days, beating the target of 30 days.
Expansion of Authorized Treatment Centers (ATCs)
Adaptimmune has 28 centers accepting referrals for TECELRA and anticipates having the full network of approximately 30 ATCs operational by the end of 2025, a year earlier than expected.
Regulatory Engagement and Future Plans
Progressed regulatory plans for lete-cel, with rolling BLA initiation anticipated before the end of 2025. Lete-cel has the potential to double the addressable patient population in the sarcoma franchise.
Positive Market Reception
No patient denials for TECELRA have been reported, indicating effective patient access and positive reception from the medical community.
DE:473A Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DE:473A Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 13, 2025 | €0.22 | €0.41 | +84.82% |
Mar 20, 2025 | €0.39 | €0.38 | -2.06% |
Nov 13, 2024 | €0.74 | €0.80 | +7.38% |
Aug 12, 2024 | €0.88 | €1.09 | +24.57% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Adaptimmune Therapeutics Plc. (DE:473A) report earnings?
Adaptimmune Therapeutics Plc. (DE:473A) is schdueled to report earning on Aug 06, 2025, TBA Not Confirmed.
What is Adaptimmune Therapeutics Plc. (DE:473A) earnings time?
Adaptimmune Therapeutics Plc. (DE:473A) earnings time is at Aug 06, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Adaptimmune Therapeutics Plc. stock?
The P/E ratio of Adaptimmune Therapeutics is N/A.
What is DE:473A EPS forecast?
DE:473A EPS forecast for the fiscal quarter 2025 (Q2) is -0.05.
